Maxim Group Keeps a Hold Rating on Capricor Therapeutics (CAPR)


Maxim Group analyst Jason McCarthy maintained a Hold rating on Capricor Therapeutics (CAPR) today. The company’s shares opened today at $0.68.

McCarthy noted:

“Capricor announced the lifting of the voluntary dosage hold on the HOPE-2 trial evaluating Dystrophy (DMD). The company also met with the FDA to discuss the potential of HOPE-2 to serve as the registration study upon study completion.”

According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.3% and a 31.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.

See today’s analyst top recommended stocks >>

Capricor Therapeutics’ market cap is currently $20.45M and has a P/E ratio of 103.91. The company has a Price to Book ratio of 2.93.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts